EF Hutton Reiterates Buy on Jasper Therapeutics, Maintains $6.85 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Michael King reiterated a Buy rating on Jasper Therapeutics (NASDAQ:JSPR) and maintained a $6.85 price target.
June 12, 2023 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Michael King reiterated a Buy rating on Jasper Therapeutics and maintained a $6.85 price target.
The Buy rating and maintained price target by EF Hutton analyst Michael King indicate a positive outlook for Jasper Therapeutics. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100